Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 65 mg

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 70 mg

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 75 mg

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

dne pharma as - naloxonhydrochlorid (vandfrit) - næsespray, opløsning i enkeltdosisbeholder - 1,26 mg/dosis

Европска Унија - Дански - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Европска Унија - Дански - EMA (European Medicines Agency)

alfasigma s.p.a. - methylthioniniumchlorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

as grindeks - sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 100 mg

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

as grindeks - sitagliptinhydrochloridmonohydrat - filmovertrukne tabletter - 50 mg

Данска - Дански - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmaménta aps - erysipelothrix rhusiopathiae serotype 2, stamme m2 (inaktiveret), leptospira interrogans serogruppe australis serovar bratislava (stamme as-05-073), leptospira interrogans serogruppe canicola serovar portland-vere (stamme ca-12-000), leptospira interrogans serogruppe grippotyphosa serovar dadas (stamme gr-01-005), leptospira interrogans serogruppe icterohaemorragiae serovar copenhageni (stamme ic-02-001), leptospira interrogans serogruppe pomona, stamme po-01-000 (inaktiveret), leptospira santarosai serogruppe tarassovi serovar gatuni (strain s1148/02), porcin parvovirus, stamme 014 (inaktiveret) - injektionsvæske, suspension

Европска Унија - Дански - EMA (European Medicines Agency)

n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporose, postmenopausale - narkotika til behandling af knoglesygdomme - behandling af postmenopausal osteoporose hos patienter med risiko for vitamin d-insufficiens. adrovance reducerer risikoen for vertebrale og hoftebrud.